Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair
Abeykoon, Jithma P. , Wu, Xiaosheng , Nowakowski, Kevin E., Dasari, Surendra , Paludo, Jonas , Weroha, S. John , Hou, Xiaonan , Mladek, Ann C. , Phillips, Jessica L. , Ravindran, Aishwarya , King, Rebecca L. , Boysen, Justin C. , Stenson, Mary, Carr, Ryan M. , Molina, Julian R. , Kapoor, Prashant , Kumar, Shaji , Yu, Jia , Wang, Liewei , Patnaik, Mrinal M. , Chen, Chen , Paludo, Jonas , Chen, C , Ravindran, Aishwarya , Mladek, Ann C , Carr, Ryan M , Hu, Chunling , Sarkaria, Jann N. , Feldman, Andrew L. , Manske, Michelle K. , Parikh, Sameer A. , Robinson, Steven I. , Boughey, Judy C. , Goetz, Matthew P. , Couch, Fergus J. , Witzig, Thomas E.

Mayo Clinic

Blood | November 3, 2020 | Volume: 137 | Issue: 4 | Pages: 513-523

10.1182/blood.2020009013 | PMID 33507295 Get It

Abstract Chromosome region maintenance protein 1 (CRM1) mediates protein export from the nucleus and is a new target for anticancer therapeutics. Broader application of KPT-330 (selinexor), a first-in-class CRM1 inhibitor recently approved for relapsed multiple myeloma and diffuse large B-cell lymphoma, have been limited by substantial toxicity. We discovered that salicylates markedly enhance the antitumor activity of CRM1 inhibitors by extending the mechanisms of action beyond CRM1 inhibition. Using salicylates in combination enables targeting of a range of blood cancers with a much lower dose of selinexor, thereby potentially mitigating prohibitive clinical adverse effects. Choline salicylate (CS) with low-dose KPT-330 (K+CS) had potent, broad activity across high-risk hematological malignancies and solid-organ cancers ex vivo and in vivo. The K+CS combination was not toxic to nonmalignant cells as compared with malignant cells and was safe without inducing toxicity to normal organs in mice. Mechanistically, compared with KPT-330 alone, K+CS suppresses the expression of CRM1, Rad51, and thymidylate synthase proteins, leading to more efficient inhibition of CRM1-mediated nuclear export, impairment of DNA-damage repair, reduced pyrimidine synthesis, cell-cycle arrest in S-phase, and cell apoptosis. Moreover, the addition of poly (ADP-ribose) polymerase inhibitors further potentiates the K+CS antitumor effect. K+CS represents a new class of therapy for multiple types of blood cancers and will stimulate future investigations to exploit DNA-damage repair and nucleocytoplasmic transport for cancer therapy in general.
Cross-talk between CDK4/6 and SMYD2 regulates gene transcription, tubulin methylation, and ciliogenesis
Li, Xiaoyan , Zhou, Julie , Wang, Xiaodong , Zhang, Hongbing , Harris, Peter C. , Calvet, James P. , Li, Xiaogang , Li, Linda Xiaoyan , Zhou, Julie Xia, Harris, Peter C , Li, Xiaogang

Mayo Clinic

Science Advances | October 30, 2020 | Volume: 6 | Issue: 44 | Pages: No page available

10.1126/sciadv.abb3154 | PMID 33127671 Get It

CDK4 and CDK6 regulate ciliogenesis and Hedgehog signaling via their novel substrate SMYD2.
Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders
Kelemen, Katalin, Saft, Leonie , Craig, Fiona E. , Nakashima, Megan O. , Wertheim, Gerald , Horny, Hans-Peter, King, Rebecca L. , Wang, Sa A. , Reichard, Kaaren K. , Orazi, Attilio , George, Tracy I. , Quintanilla‐Martínez, Leticia , Rimsza, Lisa M.

Mayo Clinic

American Journal of Clinical Pathology | October 29, 2020 | Volume: 155 | Issue: 2 | Pages: 179-210

10.1093/ajcp/aqaa244 | PMID 33367563 Get It

AbstractObjectivesTo report the findings of the 2019 Society for Hematopathology/European Association for Haematopathology Workshop within the categories of reactive eosinophilia, hypereosinophilic syndrome (HES), germline disorders with eosinophilia (GDE), and myeloid and lymphoid neoplasms associated with eosinophilia (excluding entities covered by other studies in this series).MethodsThe workshop panel reviewed 109 cases, assigned consensus diagnosis, and created diagnosis-specific sessions.ResultsThe most frequent diagnosis was reactive eosinophilia (35), followed by acute leukemia (24). Myeloproliferative neoplasms (MPNs) received 17 submissions, including chronic eosinophilic leukemia, not otherwise specified (CEL, NOS). Myelodysplastic syndrome (MDS), MDS/MPN, and therapy-related myeloid neoplasms received 11, while GDE and HES received 12 and 11 submissions, respectively.ConclusionsHypereosinophilia and HES are defined by specific clinical and laboratory criteria. Eosinophilia is commonly reactive. An acute leukemic onset with eosinophilia may suggest core-binding factor acute myeloid leukemia, blast phase of chronic myeloid leukemia, BCR-ABL1–positive leukemia, or t(5;14) B-lymphoblastic leukemia. Eosinophilia is rare in MDS but common in MDS/MPN. CEL, NOS is a clinically aggressive MPN with eosinophilia as the dominant feature. Bone marrow morphology and cytogenetic and/or molecular clonality may distinguish CEL from HES. Molecular testing helps to better subclassify myeloid neoplasms with eosinophilia and to identify patients for targeted treatments.
International guidelines for the flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: Assay development/optimization, validation, and ongoing quality monitors
Illingworth, Andrea , Johansson, Ulrika , Huang, Shuguang , Wang, Sa A. , Wolniak, Kristy , Psarra, Katherina , Torres, Richard , Craig, Fiona E. , Horna, Pedro , Craig, Fiona E , Almeida, Júlia

Mayo Clinic

Cytometry Part B: Clinical Cytometry | October 28, 2020 | Volume: 100 | Issue: 2 | Pages: 156-182

10.1002/cyto.b.21963 | PMID 33112044 Get It

AbstractIntroducing a sensitive and specific peripheral blood flow cytometric assay for Sézary syndrome and mycosis fungoides (SS/MF) requires careful selection of assay design characteristics, and translation into a laboratory developed assay through development/optimization, validation, and continual quality monitoring. As outlined in a previous article in this series, the recommended design characteristics of this assay include at a minimum, evaluation of CD7, CD3, CD4, CD8, CD26, and CD45, analyzed simultaneously, requiring at least a 6 color flow cytometry system, with both quantitative and qualitative components. This article provides guidance from an international group of cytometry specialists in implementing an assay to those design specifications, outlining specific considerations, and best practices. Key points presented in detail are: (a) Pre‐analytic components (reagents, specimen processing, and acquisition) must be optimized to: (i) identify and characterize an abnormal population of T‐cells (qualitative component) and (ii) quantitate the abnormal population (semi/quasi‐quantitative component). (b)Analytic components (instrument set‐up/acquisition/analysis strategy and interpretation) must be optimized for the identification of SS/MF populations, which can vary widely in phenotype. Comparison with expert laboratories is strongly encouraged in order to establish competency. (c) Assay performance must be validated and documented through a validation plan and report, which covers both qualitative and semi/quasi‐quantitative assay components (example template provided). (d) Ongoing assay‐specific quality monitoring should be performed to ensure consistency.
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
Mascarenhas, John , Rampal, Raajit K. , Bhave, Rupali , Hexner, Elizabeth O. , Wang, Eunice S. , Gerds, Aaron T. , Abboud, Camille N. , Kremyanskaya, Marina , Berenzon, Dimitry, Odenike, Olatoyosi , Farnoud, Noushin , Krishnan, Aishwarya , Weinberg, Rona Singer , Salama, Mohamed E. , Najfeld, Vesna , Medina-Martínez, Juan S. , Zhou, Yangyu, Sandy, Lonette, Heaney, Mark , Levine, Ross L. , Dueck, Amylou C. , Dueck, A. C. , Wang, Eunice S. , Gerds, Aaron T , Mascarenhas, John , Hexner, Elizabeth , Najfeld, Vesna , Kosiorek, Heidi , McGovern, Erin , Ossa, Juan Arango , Levine, Max F. , Mesa, Ruben A. , Hoffman, Ronald

Mayo Clinic

Blood Advances | October 26, 2020 | Volume: 4 | Issue: 20 | Pages: 5246-5256

10.1182/bloodadvances.2020002119 | PMID 33104796 Get It

Abstract Myeloproliferative neoplasms (MPN) that have evolved into accelerated or blast phase disease (MPN-AP/BP) have poor outcomes with limited treatment options and therefore represent an urgent unmet need. We have previously demonstrated in a multicenter, phase 1 trial conducted through the Myeloproliferative Neoplasms Research Consortium that the combination of ruxolitinib and decitabine is safe and tolerable and is associated with a favorable overall survival (OS). In this phase 2 trial, 25 patients with MPN-AP/BP were treated at the recommended phase 2 dose of ruxolitinib 25 mg twice daily for the induction cycle followed by 10 mg twice daily for subsequent cycles in combination with decitabine 20 mg/m2 for 5 consecutive days in a 28-day cycle. Nineteen patients died during the study follow-up. The median OS for all patients on study was 9.5 months (95% confidence interval, 4.3-12.0). Overall response rate (complete remission + incomplete platelet recovery + partial remission) was 11/25 (44%) and response was not associated with improved survival. We conclude that the combination of decitabine and ruxolitinib was well tolerated, demonstrated favorable OS, and represents a therapeutic option for this high-risk patient population. This trial was registered at www.clinicaltrials.gov as #NCT02076191.
S1108 Impact of Affordable Care Act on Cirrhosis Hospitalization Outcomes
Rojas, Ricardo L., Kamath, Marielle J., Kamath, Patrick S. , Wang, Xiao‐Jing , Borah, Bijan J. , Moriarty, James P. , Allen, Alina M.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S558-S559

10.14309/01.ajg.0000706480.92101.43 Get It

S0823 Disease Disclosure Preferences and Stigma Among Patients With Inflammatory Bowel Disease
Guo, Ling , Wang, Xinyi , Senada, Peter A., Green, Max E. , Rohde, Jacob A. , Farraye, Francis A.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S423-S423

10.14309/01.ajg.0000705340.56555.3e Get It

S0663 Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis After Treatment Interruption: An Update of Results From the OCTAVE Clinical Trials
Dubinsky, Marla C. , Sharara, Ala I. , Lawendy, Nervin, Wang, Wenjin , Salese, Leonardo , Su, Chinyu , Modesto, Irene , Panés, Julián , Colombel, Jean‐Frédéric , Vermeire, Séverine , Guo, Xiang , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S332-S332

10.14309/01.ajg.0000704700.92838.b3 Get It

S0662 Evaluating the Optimum Number of Biopsies to Assess Histologic Inflammation in Ulcerative Colitis
Pai, Rish K. , Wang, Zhongya , McDonald, John WD, Duijvestein, Marjolijn , Jeyarajah, Jenny , Parker, Claire E. , Viegen, Tanja van, Nelson, Sigrid, Boland, Brigid S. , Singh, Siddharth , Dulai, Parambir S. , Feagan, Brian G. , Sandborn, William J. , Battat, Robert , Casteele, Niels Vande , Zou, Guangyong , Valasek, Mark A. , Jairath, Vipul

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S331-S332

10.14309/01.ajg.0000704696.77507.99 Get It

S0423 “WATS” the Incremental Yield of Wide-Area Transepithelial Sampling for Dysplasia Detection in Barrett’s Esophagus? A Systematic Review and Meta-Analysis
Codipilly, Don C. , Chandar, Apoorva K., Dhaliwal, Lovekirat , Katzka, David A. , Wang, Kenneth K. , Chak, Amitabh , Iyer, Prasad G.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S211-S211

10.14309/01.ajg.0000703740.83988.52 Get It